Tag: ASX: IMM
First dose administered in Efti, BAVENCIO trial for metastatic urothelial cancer
Immutep Limited, a pioneering clinical-stage biotechnology company specializing in LAG-3 immunotherapies, announced the enrollment and safe dosing of the first patient in the INSIGHT-005 Phase I trial in the fight against metastatic urothelial carcinoma.
Immutep gets green light for large-scale cancer product manufacturing for clinical trials
Immutep Limited, a clinical-stage biotechnology company specialising in LAG-3 immunotherapies for cancer and autoimmune diseases, has received regulatory authorisation for the commercial manufacturing of Eftilagimod Alpha (efti) at a scale of 2,000 litres for clinical trial use.Â
Featured Article
From cost exposure to cost control: Using energy flexibility to protect margins
Electricity price volatility is reshaping the cost base of Australian manufacturing, challenging long-held assumptions that energy can be treated as a stable operational input.
